REGULATORY

MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis

June 26, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) has withdrawn its sakigake fast-track designation for Takeda Pharmaceutical’s proteasome inhibitor Ninlaro (ixazomib) for the treatment of immunoglobulin light chain amyloidosis (AL amyloidosis) after the company called off the program. The MHLW…

To read the full story

Takeda Updates Failed Ninlaro Trial Results for Amyloidosis
December 10, 2019
Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019

REGULATORY

LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…